Erin M. Coffee

发表

Title: Cross-Species Analysis of Genetically Engineered Mouse Models of MAPK Driven

Ping Jiang, Eva Budinská, Owen J. Sansom, 2014 .

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Mari Mino-Kenudson, Keith T Flaherty, Erin M. Coffee, 2012, Cancer discovery.

Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib

Erin M. Coffee, K. Flaherty, M. Mino‐Kenudson, 2012 .

Increased prevalence of mutant null alleles that cause hereditary fructose intolerance in the American population

Erin M. Coffee, D. Tolan, L. Yerkes, 2010, Journal of Inherited Metabolic Disease.

Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation

Peter J. Belmont, Erin M. Coffee, R. Xavier, 2013, Clinical Cancer Research.

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.

Travis J Cohoon, Erin M. Coffee, T. Shioda, 2013, Cancer cell.

Mutations in the promoter region of the aldolase B gene that cause hereditary fructose intolerance

Erin M. Coffee, D. Tolan, 2010, Journal of Inherited Metabolic Disease.

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer

Erin M. Coffee, M. Sinnamon, R. Bronson, 2011, PloS one.

Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

Erin M. Coffee, R. Xavier, J. Engelman, 2013, Clinical Cancer Research.

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.

Peter J. Belmont, Erin M. Coffee, M. Sinnamon, 2014, Cancer letters.

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease

Peter J. Belmont, Erin M. Coffee, M. Delorenzi, 2014, Disease Models & Mechanisms.

Cancer Therapy : Preclinical Concomitant BRAFandPI 3 K / mTORBlockade IsRequired for Effective Treatment of BRAFV 600 E Colorectal Cancer

Erin M. Coffee, R. Xavier, J. Engelman, 2013 .

Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Erin M. Coffee, K. Flaherty, M. Mino‐Kenudson, 2012 .

Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations

Erin M. Coffee, L. Garraway, A. Iafrate, 2015 .

Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models

Travis J Cohoon, Erin M. Coffee, T. Shioda, 2013 .

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Erin M. Coffee, S. Ramaswamy, M. Rivera, 2014, Cancer discovery.

ConcomitantBRAFandPI3K/mTORBlockadeIsRequiredfor Effective Treatment of BRAF V600E Colorectal Cancer

Erin M. Coffee, R. Xavier, J. Engelman, 2013 .

Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

Erin M. Coffee, R. Xavier, J. Engelman, 2013, Clinical Cancer Research.

Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation

Peter J. Belmont, Erin M. Coffee, R. Xavier, 2013, Clinical Cancer Research.